Actuate Therapeutics (ACTU) News Today $8.25 +0.24 (+3.00%) (As of 03:37 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 16 at 1:09 AM | marketbeat.comActuate Therapeutics' (NASDAQ:ACTU) Quiet Period Set To Expire on September 23rdActuate Therapeutics' (NASDAQ:ACTU - Get Free Report) quiet period will expire on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its IPO on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.September 11, 2024 | finanznachrichten.deActuate Therapeutics: Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue SarcomasSeptember 11, 2024 | marketwatch.comActuate Gets FDA Orphan Designation for Elraglusib in Soft Tissue SarcomasSeptember 11, 2024 | americanbankingnews.comContrasting Actuate Therapeutics (ACTU) and Its CompetitorsSeptember 9, 2024 | globenewswire.comActuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing SarcomaSeptember 5, 2024 | globenewswire.comActuate to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 18, 2024 | investing.comActuate therapeutics insider sells $150,000 worth of sharesAugust 17, 2024 | investing.comActuate Therapeutics Inc (ACTU)August 17, 2024 | insidertrades.comActuate Therapeutics (NASDAQ:ACTU) Insider Todd S. Thomson Sells 18,750 SharesAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust FinancialsAugust 15, 2024 | ca.finance.yahoo.comActuate Therapeutics, Inc. Common stock (ACTU)August 15, 2024 | insidertrades.comActuate Therapeutics (NASDAQ:ACTU) Major Shareholder Leslie W. Kreis Sells 24,999 SharesAugust 14, 2024 | globenewswire.comActuate Therapeutics Announces Closing of Initial Public OfferingAugust 12, 2024 | globenewswire.comActuate Therapeutics Announces Pricing of Initial Public Offering Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address Introducing the Perceptron (Ad)On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016. Just click here to register. ACTU Media Mentions By Week ACTU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACTU News Sentiment▼0.310.68▲Average Medical News Sentiment ACTU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACTU Articles This Week▼63▲ACTU Articles Average Week Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MREO News Today YMAB News Today IGMS News Today EXAI News Today VECT News Today TRDA News Today SIGA News Today LRMR News Today SLN News Today RGNX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACTU) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACTU Stock Alerts